Key points are not available for this paper at this time.
elevates oxidative stress and sustainably suppresses bacterial proliferation for a long time. The combination of these two aspects endows the Ag@BP nanohybrids with synergistically enhanced antibacterial performance. Different from traditional antibiotics, the antibacterial effects of the Ag@BP nanohybrids are independent of the bacterial structure, which bypasses the issue of drug resistance. The in vivo studies show that the Ag@BP nanohybrids efficiently decrease the MRSA bacterial burden in mice and minimize infection associated tissue lesions. Besides, the excellent biocompatibility of the Ag@BP nanohybrids guarantees their biosafety for future clinical applications. Accordingly, this work demonstrates the potential of the BP nanosheets in the synergistic antibacterial therapy against drug resistant bacteria, and paves the way for developing 2D semiconductor based synergistic antibacterial nanodrugs.
Ouyang et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: